Skip to content

CROI: Low rates of resistance seen in Staccato trial of CD4-guided treatment interruptions

CROI News Feature: Experts divided over the future of treatment interruptions

CROI: CD4-guided treatment interruptions unsafe, SMART study concludes

Treatment interruption study stopped after excess number of AIDS events seen in people taking treatment breaks

ICAAC: Viral load between six to 18 months predicts longer-term success of HIV therapy

CD4 cell count below 250 associated with shorter treatment break

Efavirenz may linger for up to eight weeks after treatment stops

NNRTIs have a greater risk of resistance than PIs when used in regimens after treatment break

IAS: Remune slows viral load rise and CD4 cell count fall during treatment interruptions